B+
Bull case
0%
Probability
Target price
$255.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
LGND
LigandDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
1%
Probability
Target price
$228.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$180.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-09
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+34.2
Score
AI commentary
The near-term tone is mixed. Primary company materials support a solid royalty-growth quarter, reaffirmed full-year guidance, and tangible portfolio expansion logic from XOMA, but the immediate market read-through was still shaped by the revenue/EPS miss and a sharp opening gap lower on May 7, 2026. T+3 analyst-revision evidence was not meaningfully visible in the sources checked, so this remains a cautious post-earnings monitoring view rather than a high-conviction bullish reset.
RankAlpha Sentiment Codex - 2026-05-09
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-15catalystQ1 earnings miss is now offset against reaffirmed full-year guidanceMedium impact
Ligand reported Q1 2026 royalty revenue growth of 56% year over year, but total revenue of $51.7 million and adjusted EPS of $1.63 still trailed the consensus figures visible in checked secondary coverage, while management reaffirmed the previously raised 2026 outlook after the XOMA announcement. The near-term setup is therefore a post-print digestion period where investors decide whether the miss was mainly timing and mark-to-market noise or a signal that the royalty model is less predictable than the premium multiple implies [#8-K-2026-05-07] [#10-Q-2026-05-08].
2026-09-30eventPending XOMA Royalty acquisition is the main 2026 portfolio-expansion triggerHigh impact
Ligand said the XOMA Royalty acquisition is expected to close in Q3 2026 and would add more than 120 assets, including seven commercial assets and 14 late-stage programs, with about $25 million of partial-year royalty revenue contribution assumed in the raised 2026 outlook. If the deal closes on time and integration is clean, it would deepen portfolio scale and diversification; if timing slips or financing and synergy assumptions prove too optimistic, the current growth case loses some of its most visible support [#8-K-2026-05-07].
2026-11-15catalystLate-stage partner asset progress still matters, with Qtorin NDA timing one visible second-half testMedium impact
Ligand highlighted that Palvella's Qtorin rapamycin NDA submission for microcystic lymphatic malformations remains on track for the second half of 2026 after positive Phase 3 data. This is not near-term earnings support, but it does matter for preserving the market view that Ligand can keep stacking new royalty-bearing programs beyond the current commercial leaders [#8-K-2026-05-07].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-09 • Updated nightlySource: Internal modelMethodology